Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson stent sees blood clot risk fall

Johnson and Johnson stent sees blood clot risk fall

5th September 2007

Johnson and Johnson has announced that the CYPHER Sirolimus-eluting coronary stent has been shown in the largest study conducted to date to result in notable reductions to the risk of clotting and reintervention compared with the Taxus stent.

A meta-analysis trial conducted using the stents found that the CYPHER stent demonstrated lower risks for 30 months after the angioplasty.

The analysis consisted of 16 randomised trials involving 8,695 patients, the results of which have now been detailed on the American College of Cardiology.

Professor Albert Schomig, MD, from Deutsches Herzzentrum, Technische Universitat in Munich, explains: “Over the past year, concerns have been raised regarding the long-term safety of all drug-eluting stents.

“This [meta-analysis] reinforces the notion that there are marked differences between the CYPHER stent and the Taxus stent and that the safety of these drug-eluting stents must be assessed separately.”

Last year MedicalNewsToday.com reported that a randomised clinical trial demonstrated the higher performance of the CYPHER stent than the Taxus stent in procedures involving long coronary lesions.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.